Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 1
2017 1
2019 2
2020 7
2021 4
2022 2
2023 2
2024 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

24 results

Results by year

Filters applied: . Clear all
Page 1
The HIV-1 reservoir landscape in persistent elite controllers and transient elite controllers.
Gasca-Capote C, Lian X, Gao C, Roseto IC, Jiménez-León MR, Gladkov G, Camacho-Sojo MI, Pérez-Gómez A, Gallego I, Lopez-Cortes LE, Bachiller S, Vitalle J, Rafii-El-Idrissi Benhnia M, Ostos FJ, Collado-Romacho AR, Santos J, Palacios R, Gomez-Ayerbe C, Muñoz-Medina L, Ruiz-Sancho A, Frias M, Rivero-Juarez A, Roca-Oporto C, Hidalgo-Tenorio C, Rull A, Olalla J, Lopez-Ruz MA, Vidal F, Viladés C, Mastrangelo A, Cavassini M, Espinosa N, Perreau M, Peraire J, Rivero A, López-Cortes LF, Lichterfeld M, Yu XG, Ruiz-Mateos E. Gasca-Capote C, et al. Among authors: roca oporto c. J Clin Invest. 2024 Feb 20;134(8):e174215. doi: 10.1172/JCI174215. J Clin Invest. 2024. PMID: 38376918 Free PMC article.
Vedolizumab and ART in recent HIV-1 infection unveil the role of α4β7 in reservoir size.
Jimenez-Leon MR, Gasca-Capote C, Roca-Oporto C, Espinosa N, Sobrino S, Fontillon-Alberdi M, Gao C, Roseto I, Gladkov G, Rivas-Jeremias I, Neukam K, Sanchez-Hernandez JG, Rigo-Bonnin R, Cervera-Barajas AJ, Mesones R, García F, Alvarez-Rios AI, Bachiller S, Vitalle J, Perez-Gomez A, Camacho-Sojo MI, Gallego I, Brander C, McGowan I, Mothe B, Viciana P, Yu X, Lichterfeld M, Lopez-Cortes LF, Ruiz-Mateos E. Jimenez-Leon MR, et al. Among authors: roca oporto c. JCI Insight. 2024 Jul 9;9(16):e182312. doi: 10.1172/jci.insight.182312. JCI Insight. 2024. PMID: 38980725 Free PMC article. Clinical Trial.
Plasma concentrations of IL-6, MIP-1β, IP-10, and PTX-3 as predictors of the immunological response to antiretroviral treatment in people with HIV.
Mejías-Trueba M, Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodríguez M, Muñoz-Muela E, Llaves-Flores S, Espinosa N, Roca-Oporto C, Herrero M, Sotomayor C, López-Cortes LF. Mejías-Trueba M, et al. Among authors: roca oporto c. Front Immunol. 2024 Aug 29;15:1447926. doi: 10.3389/fimmu.2024.1447926. eCollection 2024. Front Immunol. 2024. PMID: 39267754 Free PMC article. Review.
Toll-like receptor agonists enhance HIV-specific T cell response mediated by plasmacytoid dendritic cells in diverse HIV-1 disease progression phenotypes.
Jimenez-Leon MR, Gasca-Capote C, Tarancon-Diez L, Dominguez-Molina B, Lopez-Verdugo M, Ritraj R, Gallego I, Alvarez-Rios AI, Vitalle J, Bachiller S, Camacho-Sojo MI, Perez-Gomez A, Espinosa N, Roca-Oporto C, Rafii-El-Idrissi Benhnia M, Gutierrez-Valencia A, Lopez-Cortes LF, Ruiz-Mateos E. Jimenez-Leon MR, et al. Among authors: roca oporto c. EBioMedicine. 2023 May;91:104549. doi: 10.1016/j.ebiom.2023.104549. Epub 2023 Apr 3. EBioMedicine. 2023. PMID: 37018973 Free PMC article.
Long-term effectiveness, safety, and tolerability of doravirine in antiretroviral-experienced people with HIV in real life.
Mejías-Trueba M, Gutierrez-Valencia A, Llaves-Flores S, Roca-Oporto C, Herrero M, Sotomayor de la Piedra C, Lopez-Cortes LF, Espinosa N. Mejías-Trueba M, et al. Among authors: roca oporto c. Microbiol Spectr. 2024 Aug 6;12(8):e0065424. doi: 10.1128/spectrum.00654-24. Epub 2024 Jun 25. Microbiol Spectr. 2024. PMID: 38916326 Free PMC article.
Long-term effects on immunological, inflammatory markers, and HIV-1 reservoir after switching to a two-drug versus maintaining a three-drug regimen based on integrase inhibitors.
Saborido-Alconchel A, Serna-Gallego A, Trujillo-Rodriguez M, Muñoz-Muela E, Álvarez-Ríos AI, Lozano C, Llaves-Flores S, Espinosa N, Roca-Oporto C, Herrero M, Sotomayor C, Gutierrez-Valencia A, Lopez-Cortes LF. Saborido-Alconchel A, et al. Among authors: roca oporto c. Front Immunol. 2024 Jul 11;15:1423734. doi: 10.3389/fimmu.2024.1423734. eCollection 2024. Front Immunol. 2024. PMID: 39055703 Free PMC article. Clinical Trial.
Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection.
Pérez-Gómez A, Vitallé J, Gasca-Capote C, Gutierrez-Valencia A, Trujillo-Rodriguez M, Serna-Gallego A, Muñoz-Muela E, Jiménez-Leon MLR, Rafii-El-Idrissi Benhnia M, Rivas-Jeremias I, Sotomayor C, Roca-Oporto C, Espinosa N, Infante-Domínguez C, Crespo-Rivas JC, Fernández-Villar A, Pérez-González A, López-Cortés LF, Poveda E, Ruiz-Mateos E; Virgen del Rocío Hospital COVID-19 Working Team. Pérez-Gómez A, et al. Among authors: roca oporto c. Cell Mol Immunol. 2021 Sep;18(9):2128-2139. doi: 10.1038/s41423-021-00728-2. Epub 2021 Jul 21. Cell Mol Immunol. 2021. PMID: 34290398 Free PMC article.
Decay kinetics of HIV-1-RNA in seminal plasma with dolutegravir/lamivudine versus dolutegravir plus emtricitabine/tenofovir alafenamide in treatment-naive people living with HIV.
Saborido-Alconchel A, Serna-Gallego A, Lopez-Cortes LE, Trujillo-Rodriguez M, Praena-Fernandez JM, Dominguez-Macias M, Lozano C, Muñoz-Muela E, Espinosa N, Roca-Oporto C, Sotomayor C, Herrero M, Gutierrez-Valencia A, Lopez-Cortes LF. Saborido-Alconchel A, et al. Among authors: roca oporto c. J Antimicrob Chemother. 2023 Sep 5;78(9):2354-2360. doi: 10.1093/jac/dkad245. J Antimicrob Chemother. 2023. PMID: 37545387 Free PMC article. Clinical Trial.
24 results